Trials / Completed
CompletedNCT01473394
Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder
A Double-blind, Placebo-controlled, Fixed-dose Study of Vilazodone in Patients With Major Depressive Disorder
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 518 (actual)
- Sponsor
- Forest Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to further characterize the efficacy, safety, and tolerability of a single fixed dose level of vilazodone compared to placebo in patients with major depressive disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dose-matched placebo | Dose-matched placebo was supplied as tablets. |
| DRUG | Vilazodone | Vilazodone was supplied as tablets. |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2013-02-01
- Completion
- 2013-02-01
- First posted
- 2011-11-17
- Last updated
- 2014-04-03
- Results posted
- 2014-04-03
Locations
14 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01473394. Inclusion in this directory is not an endorsement.